Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Investment analysts at Leerink Swann lifted their Q3 2016 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research report issued to clients and investors on Monday. Leerink Swann analyst J. Schwartz now expects that the brokerage will post earnings per share of ($1.25) for the quarter, up from their previous estimate of ($1.34). Leerink Swann currently has a “Market Perform” rating and a $50.00 target price on the stock. Leerink Swann also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.18) EPS, FY2016 earnings at ($5.09) EPS, FY2017 earnings at ($3.79) EPS and FY2018 earnings at ($2.24) EPS.

Other equities analysts have also issued reports about the stock. Oppenheimer Holdings Inc. boosted their price target on shares of Sarepta Therapeutics from $60.00 to $76.00 in a research report on Monday. Vetr upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price target on the stock in a research report on Thursday, June 2nd. WBB Securities restated a “buy” rating and set a $40.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, June 8th. Robert W. Baird restated a “buy” rating on shares of Sarepta Therapeutics in a research report on Friday, June 10th. Finally, Needham & Company LLC lifted their target price on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, July 22nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $51.01.

Sarepta Therapeutics (NASDAQ:SRPT) traded up 6.55% during trading on Thursday, hitting $59.90. 5,206,352 shares of the stock were exchanged. The stock’s market cap is $2.87 billion. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $60.00. The stock’s 50 day moving average price is $29.05 and its 200 day moving average price is $21.62.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/research-analysts-set-expectations-for-sarepta-therapeutics-inc-s-q3-2016-earnings-srpt.html

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the company posted ($0.87) EPS.

In other news, VP Jayant Aphale sold 35,000 shares of the company’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,750,000.00. Following the completion of the transaction, the vice president now owns 21,490 shares in the company, valued at approximately $1,074,500. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Fund Advisors boosted its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares during the last quarter. State Street Corp boosted its position in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares during the last quarter. Commonwealth Equity Services Inc bought a new position in shares of Sarepta Therapeutics during the second quarter valued at about $302,000. National Planning Corp boosted its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in shares of Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock valued at $4,230,000 after buying an additional 11,334 shares during the last quarter. Institutional investors and hedge funds own 72.09% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.